Background: RSV infection is an important cause of respiratory disease in HT recipients. In these patients, RSV upper and lower respiratory tract infection (URTI and LRTI), if untreated, progress to pneumonia in at least 25% cases. Once pneumonia develops, its mortality is over 80% with no treatment, and still very high (60%) with the best antiviral and support management. Early diagnosis and prompt treatment of RVS infection to prevent progression to pneumonia is a standard practice in many BMT centres. But, because of the lack of randomised prospective studies, the gold standard for the management of RSV disease in HT recipients is not well established yet. We describe the characteristics and outcome of a group of patients with symptomatic RSV infection treated with aerosolised Ribavirin. Patients and methods: Fifteen patients undergoing HT (12 allogeneic -1 unrelated-and 3 autologous) were diagnosed with symptomatic RSV infection. It occurred in winter (January through March) in 13 cases, in October in one case, and in May in another one. The patients' ages ranged from 14 to 69 years old (median: 48). Conditioning was BuCy (6), Fludarabine-based (4), Cy-TBI (2), BuMel (1), Mel-140 (1), and BEAM (1). Stem cell source was PB in 12 cases and BM in 3. The day of transplant at the onset of the infection ranged from +2 to +840 (median: +105). Seven patients were lymphopenic, while just one was neutropenic. Most of the allogeneic HT patients (10 out of 12) had GVHD and/or immunosuppressive therapy. Nine patients had URTI, 3 LRTI and 3 pneumonia. In addition to other microbiological tests, studies for RSV were performed in HT patients with acute respiratory symptoms by means of indirect immunofluorescence. In most cases, specimens consisted of profound nasopharingeal washes; bronchial aspirates and BAL were also studied when available. All patients with documented RSV infection received aerosolised Ribavirin at 2 gr. over 2 hours three times a day for seven days; one patient treated for advanced pneumonia died without having finished the treatment. Intravenous immunoglobulin was added in 9 cases. Results: In all patients (12) treated for URTI or LRTI (pre-emptive treatment) the illness resolved with no progression to pneumonia. Two of the three patients who received the treatment for pneumonia succumbed to the infection. There were no major adverse effects due to the therapy. Conclusions: In HT recipients, pre-emptive therapy for RSV disease with aerosolised Ribavirin was a safe and efficient approach to prevent progression to pneumonia and death. Like in previous reports, in our series RSV pneumonia had a high mortality rate in spite of the therapy, particularly if Ribavirin was started when pneumonia was advanced.
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Profile of infectious complications following allogeneic HLAidentical sibling transplantation with anti-T-lymphocyte globulin-based reduced-intensity preparative regimen M. Mohty, W. Jacot, C. Faucher, L. Collet, C. Zandotti, K. Bilger, N. Vey, A.M. Stoppa, D. Coso, P. Viens, C. Chabannon, J.A. Gastaut, D. Maraninchi, D. Blaise (Marseille, F) Reduced-intensity preparative regimen (RIC) has been shown to allow engraftment with minimal early TRM. However, in the context of RIC, the profile of infectious complications remains unknown. In this report, we analyzed the features of 75 consecutive high risk patients who received a RIC including fludarabine, busulfan and anti-T lymphocyte globulin (ATG, ImtixSangstat). Median age of recipients was 50 y. . 31 patients (41%) were treated for myeloid malignancies, whereas 29 patients (39%) had lymphoid malignancies. 15 (20%) patients had refractory metastatic non-hematological malignancies. 38 patients received a BM graft, whereas 37 received PBSC. 8 donor/recipient pairs (11%) were CMV seronegative. As part of the protocol, the ATG dose was progressively decreased from 10 mg/kg to 2.5 mg/Kg with the aim of modulating GVHD and toxicity. 40 patients received the higher ATG dose (10 or 7.5 mg/kg), while 35 patients received the lower ATG dose of 2.5 mg/Kg. ANC >500/µL and platelet engraftment were reached respectively at a median of 15 days (range, 9-23) and 14 days (range, 0-99). 34 patients experienced a CMV blood infection episode at a median of 35 days (range, 7-104). The cumulative incidence of CMV reactivation reached 45% (95% CI, 34%-56%). None of these patients developed a CMV disease, and 44% of CMV infections occurred while patients had not experienced any sign of acute GVHD. When looking for factors predictive of the likelihood of CMV reactivation, the latter was significantly associated with the ATG dose infused during conditioning (high ATG dose, 60% vs. low ATG dose, 28%; P= .006). 19 patients (25%; 95% CI, 15%-35%) experienced a bacterial infection at a median of 67 days (range, 7-172) post-allo-SCT, of whom only one infection during the neutropenic phase. Gram negative bacteria were the main source of bacterial infections (68%). The cumulative incidence of fungal infections (6 invasive aspergillosis and 2 others) reached 9% (95% CI, 3%-16%) occurring at a median of 80 days (range, 7-166) post-allo-SCT. Overall, with a median FU of 532 days (range, 149-1326), only 5 patients (7%; 95% CI, 2%-15%) died of infectious complications of whom 3 from invasive aspergillosis. Collectively, these results suggest that a low ATG dose-based RIC allo-SCT is associated with a low incidence of infections without an increased TRM, thus providing a platform for the refinement of low intensity approaches designed to enhance the GVT effect with an acceptable risk of infections.
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Autologous hematopoietic stem cell transplantation of Crohn's disease R. Burt, R. Craig, A. Traynor, Y. Oyama (Chicago, USA) Eight patients with severe Crohn's disease, defined by a Crohn's Disease Activity Index (CDAI) greater than 250 despite antitumor necrosis factor alpha (remicaide) have been enrolled (2 awaiting treatment), six have been mobilized, and five have been treated by intense immune suppression and autologous hematopoietic stem cell transplantation (HSCT). Stem cells were mobilized from the peripheral blood using cyclophosphamide (2.0 g/m2) and G-CSF (10 ug/kg/day), enriched ex vivo by CD34+ selection (isolex), and reinfused after immune conditioning with cyclophosphamide (200 mg/kg) and anti-thymocyte globulin (ATG) (90 mg/kg). HSCT were complicated by 24-48 hours of culture negative fever. Patients diarrhea and abdominal pain resolved prior to hospital discharge. Perianal fistulae gradually closed over several months, and abdominal masses and colonic strictures have resolved. All patients have remained in clinical remission (CDAI < 100) since HSCT (range 3-18 months) off all immune suppressive or modulating drugs. Albumin, hemoglobin, and weight have improved or normalized. Small bowel radiographs have gradually normalized over 12 months. Colonoscopy has revealed marked improvement but occasional asymptomatic ulcerations remain. We report the worlds first HSCTs for an indication of Crohn's disease. We conclude that further investigations of HSCT for Crohn's disease are warranted
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Long-term follow-up after autologous stem cell transplantation for refractory juvenile idiopathic arthritis I. de Kleer, D. Brinkman, A. Ferster, A. van Royen, R. ten Cate, L. Wedderburn, G. Horneff, J. Oppermann, F. Zintl, H. Foster, A.M. Prieur, A. Fasth, W. Kuis, N.M. Wulffraat (Utrecht, Leiden, NL; London, UK; Brussels, B; Halle, Jena, Cottbus, D; New Castle Upon Tyne, UK; Paris, F; Gothenburg, S) Since 1997 Autologous Stem Cell Transplantation (ASCT) has been applied as an experimental procedure in more than 40 children with refractory juvenile idiopathic arthritis (JIA). In order to evaluate feasibility, safety and efficacy we combined follow up on 28 children with systemic JIA and 6 with polyarticular JIA patients who were treated with ASCT in 9 different European transplant centers. In these 34 cases, 3 different conditioning regimens were used. The first regimen included 4 days of (ATG, 5 mg per Kg x 4; cyclophosphamide 50 mg/kg x4 and low dose TBI, 4 gray, single fraction on day -1. The second regimen included the above scheme without the low dose TBI. The third protocol included fludarabine (30 mg/m² x 2; cyclophosphamide 50 mg/kg/day x 4 and ATG (5 mg/kg x 4), methylprednisolone (1 g/m² x 4) and no TBI. Rheumatological evaluation was performed by collecting data on joint counts, global physician's scores, disability scores such as CHAQ, EPM-ROM, and ESR. These are internationally validated parameters to describe response to treatment in JIA. The clinical follow up of the children ranged from 12 to 54 months. The immunosuppressive preparative regimen induced an aplastic period of 8 to 30 days. Infectious complications were seen frequently. Nineteen patients (56%) with a follow up of 12 to 54 months achieved a drug free complete remission. Seven patients (21%) showed a partial response ranging from 30-70% decrease in disease activity compared to basal value) and 7 patients showed a complete relapse. No differences in response could be found between patients conditioned with or without TBI. There were three cases (9%) of Transplant Related Mortality due to a Macrophage Activation Syndrome. Two patients (6%) who suffered a persistent relapse died of an infection 13 and 15 months after ASCT. ASCT in severely ill JIA patients induces a drug-free remission of the disease and a profound increase in general well-being in a substantial part of the patients. However, the procedure carries a significant mortality risk for patients with this non-lethal disorder.
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Hematopoietic stem cell transplant for severe SLE: outcome of 28 patients transplanted over 6 years at a University Hospital, United States A. Traynor, W. Barr, R. Rosa, S. Ahya, T. Corbridge, Y. Oyama, J. Rogdriguez, R. Burt (Chicago, USA) Twenty-eight individuals, with active SLE in spite of monthly intravenous cyclophosphamide and other steroid sparing agents, were accepted for autologous hematopoietic stem cell transplant (HSCT) at Northwestern University. Sixteen were critically ill. All were confined to bed and to home or hospital. Organ systems effected included: active CNS disease in 17, active glomerulonephritis in 8, active pulmonary disease in 5, cardiac disease in 2, refractory muco-cutaneous disease in 2, profound thrombocytopenia in 1, profound hemolytic anemia in 1 and catastrophic anti-phopospholipid syndrome in 1. All 28 HSCT recipients are alive. Eighteen of these individuals underwent neurocognitive testing prior to HSCT. All 18 tests were abnormal. Sixteen patients have now been followed for over one year post HSCT (12-74 months). Twelve of the 16 are taking no form of immune suppression and have no evidence of SLE. Three are taking 10 mg of prednisone per day or less. One suffered full relapse and is receiving IV cyclophosphamide. Ten have undergone repeat neurocognitive testing; all have shown marked improvement post HSCT Of the 6 patients with anti-phospholipid antibodies and a history of thrombosis, all now have negative anti-phospholipid antibody tests and each is no longer receiving anti-coagulation. Four patients were on hemodialysis for over two years prior to HSCT, with persistently active SLE. Each tolerated transplant well. Pulmonary function testing is now normal in all patients followed for 6 months or more post HSCT. The two patients undergoing HSCT for refractory muco-cutaneous diease both experienced recurrence of that manifestation within a year of transplant and responded to anti-CD20 antibody. These observations form the basis for a Phase III, multi-center comparison of HSCT to a continuation of standard dose cyclophosphamide in severe SLE. Methods: Eligible patients underwent HSC mobilization with cyclophosphamide (CYCLO) (4g/m2) + G-CSF (5ug/kg/day) or G-CSF alone (10 microg/kg/day) if left ventricular ejection fraction (LVEF) < 40% until last apheresis to obtain at least 2.5x 106 CD 34+/kg. Conditioning used CYCLO (200 mg/kg) or melphalan (140 mg/m2) if LVEF <40% prior to CD34+ HSC reinjection. Evolution was recorded daily up to the end of the aplasia and then every 3 months. We analysed: 1) failure of HSC mobilization, CD34+ selection, or hematological reconstitution or procedure related death; 2) toxic events, according to WHO classification; 3) clinical response segregating major (MR), partial (PR)and no response (NR), disease progression (PRO) or relapse (REL). Results (median, range): 14 SC, 3M, 2 LE, 1 RA were included in 40 months. HSC mobilisation was successful in 12 SC, 1 M, 1 LE. It led to death from septic shock in 1 LE. Yield was not enough to allow CD34+ selection in 1 SC and 1 MY. After 2 (1-3) aphereses, the total number of CD34 + collected per patient was 7.106 CD 34+/kg (4.09-34.3). Autologous peripheral (11 SC, 3 MY, 1 LE, 1 RA) or bone marrow (1 SC) transplantation was performed with 1 procedure related death in 1 SC and 1 death form original disease in 1 MY. Median time to neutrophil > 500/mm3 and platelet > 25 000/mm3 was respectively 10 (9-14) and 9 (7-12) days. After 21 (6-33) months, 2/11 SSc had no response and 9 showed improved functional status (SHAQ) at 6 (n=10) and 9 (n=8) months (p<0.05) and regression of skin sclerosis (Rodnan modified) at 3 (n=11), 6 (n=10), 9 (n=8) , 12 (n=8) months (p<0.001) when compared to inclusion with MR (n=6) or PR (n=3). 4MR and 1PR eventually relapsed with secondary MR (n=2) or PR (n=2) with immunosuppression. After 36 (0-36) months, no MY responded with 2 deaths. CR was observed in 1 LE after 18 months and 1 RA after 6 months. Conclusion: Autologous HSC transplantation is feasible with low toxicity and significant clinical benefits in SC, underlying the need to compare HSC to monthly CYCLO in European phase III ASTIS trial. The low number of RA, LE and MY patients included in this national trial call for European studies on a larger scale.
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Immunoablative therapy with autologous stem cell transplantation in the treatment of 21 patients with poor-risk multiple sclerosis T. Kozak The immunoablative therapy with haematopoietic stem cell transplantation represents an encouraging method for patients with intractable multiple sclerosis (MS). 25 patients with poor risk MS were included to the phase I/II clinical trial involving the high dose chemotherapy with autologous peripheral blood progenitor cell (PBPC) rescue. 21 patients underwent high dose conditioning BEAM. T cell depletion in vitro was performed in 13 grafts, in vivo with ATG in 8 patients. Median follow-up was 24 months (6-46). Median EDSS of grafted patients at the time of inclusion were 6.5 (5.0-8.5), median EDSS of grafted patients at the last follow up was also 6.5 (5.0-10.0). Three patients (14%) improved, 5 patients (24%) improved not significantly (by 0.5 point). Eight patients (38%) did not change their EDSS. Two patients (9%) gained their disability significantly despite the treatment, one of them died 31 months after the transplantation from disease progression (EDSS 10.0). Three other patients (14%) worsened not significantly (by 0.5 point) on their EDSS. Altogether patients who stabilized their disability or improved represent 76%. Patients who did not worsened significantly represent 81%. Changes between the EDSS before and after the transplantation in the group were not significant. The development of disability between the group that was grafted with purged graft and the group with ATG was also not significant. No mortality has been observed in this cohort. However, the toxicity of the transplantation differed in each individual; two serious events have been observed. The first was respiratory failure after the onset of mucositis in the patient with severe pontomesncephalic impairment, the second one was sepsis with respiratory failure following bilateral pulmonary hemorrhage. Both patients needed temporary artificial ventilation. We followed changes in lymphocyte subsets before and after the treatment. Twelve months after the transplantation percentage of CD4+ cells and CD4+CD45% as well as IRI is still significantly decreased. As the significant majority of patients at least stabilized in their disability, we consider the results to be very promising. However, further follow up is needed to finally assess clinical effectiveness of immunoablative therapy in this study.
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Immunological reconstitution after T-cell depleted autologous stem cell transplantation in multiple sclerosis and non T-cell depleted autologous stem cell transplantation for hematological malignancies P. A.W. te Boekhorst, M.R. Schipperus, J.P.A. Samijn, J.J. Cornelissen, R.Q. Hintzen, P.A. van Doorn, B. Löwenberg, J.-W. Gratama (Rotterdam, The Hague, NL) Introduction: We treated 8 patients with Multiple Sclerosis (MS) with T-cell depleted autologous stem cell transplantation (ASCT). We studied the quality of immunological regeneration after this treatment. Effectivity of T -cell depletion and immunological recovery were compared with results obtained from non T-cell depleted ASCT in patients (n=30) with hematological malignancies (HM). Methods: Rigourous T-cell depletion was obtained by using a conditioning regimen consisting of TBI, ATG, and cyclophosphamide in combination with a CD34 positive selected autograft. The results of immunological recovery were obtained before and at 2, 3, 6, 9, and 12 months after ASCT. Results in healthy individuals (n=160) provided normal values. Assays included flowcytometric analysis of absolute numbers of lymphocyte subsets (e.g. CD3, CD4, CD4/CD45RO-, CD4/CD45RO+, CD8, CD27, CD56, CD62L), induction of CD69 expression by the comitogenic monoclonal antibody CD2&CD2R in CD4 and CD8 positive T -cells, and cytokine production (interferon-gamma, IL-2, TNF-alpha, IL-4, and IL-13) by the CD4 and CD8 positive T-cells after PMA&ionomycin stimulation. Results: Before ASCT, absolute counts of various T -cell populations, expression of activation markers (CD95/HLA-DR) and cytokine induction were within the normal range in MS patients. In contrast, patients with HM had a reduced CD4 (subsets) counts, strongly increased activation markers and a tendency of an enhanced cytokine production after stimulation already at the time of ASCT. Following ASCT, profiles of T-cell (subset) counts in patients with MS and patients with HM were similar. Absolute counts were subnormal. Cytotoxic T-cells (CD8/CD57+) as well as NK cells (CD3-, CD16+ and/or CD45RO+) showed a rapid recovery. In contrast, a remarkebly slow recovery of CD45 'naive'(45RO-) and to a lesser extent of CD45 'memory' (45RO+) cells was observed in both groups. CD69 expression by CD4 and CD8 T-cells after stimulation remained normal at all time points after ASCT. After 1 year, induction of cytokine production was similar in both patient groups. However, at this timepoint, significant differences were lower CD95 expression, and after stimulation, lower CD69 expression on CD4 and CD8 positive T-cells in MS patients. Conclusions: Rigorous immune suppression with ASCT in MS patients was effective in reducing T -cell populations. This resulted in prolonged deficiencies of 'naive' and 'memory' CD4 cells extending beyond 12 months.
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Autologous hematopoietic stem cell transplant for refractory Behçet's disease
A.M. Marmont, F. Gualandi, M.T. van Lint, A. Bacigalupo (Genoa, I)
Behçet's disease (BD) is an inflammatory disorder characterized by recurrent orogenital lesions, uveitis and skin lesions (1). Central nervous system (CNS) and pulmonary involvment are extremely poor prognostic signs. The etiology is unknown, but there is evidence for a pathogenetic autoimmune reaction also characterized by a clonal expansion of autoreactive T cells (2). There is a strong association with HLA-B51 in eastern Mediterranean countries, but sporadic cases occur, and these do not have the same HLA-associations. Three very severe BD cases have been treated with Autologous hematopoietic stem cell transplant (ASCT), and in 2 published ones the outcome was good, with long-term remissions up to the time of this writing (3). We report here a fourth case of severe BD treated successfully with ASCT. UPN 2043 is is a 30 year old lady not of Eastern ethnicity suffering with relapsing BD over the last 10 years. In 2001 she also suffered with uveomeningitis, followed by severe chronic refractory headache. RMN was negative, but there were EEG irregularities and a vasculitic fundic pattern. She was HLA-B51 negative. She had been refractory to all treatments including HD corticosteroids and CY. Two mobilization procedures were performed, each with CY 4g/m2 plus G-CSF, adding to a total of 5.63 CD34+ cells /Kg. Each procedure was followed by a complete remission of headache and ulcers, which tended to reappear after 3 weeks. In October, 2002 she was conditioned with the full BEAM protocol, which is the standard conditioning regimen for multiple sclerosis in our group (4). She was reconstituted with unmanipulated ASC, CD34+ 3.2 /Kg. There was a dramatic complete abrogation of all clinical symptoms.Time to ANC 500 was 9 days, and to 20x106/L platelets 10. The patient is A & W with no steroids. Although cases are few it appears that HD-IS followed by ASCT abrogates all signs and symptoms of BD. It may accordingly considered as the best rscue treatment available for chronic, refractory BD. Remission duration will have to be established. Intense IS suppresses the autoimmune response as in other severe autoimmune diseases (5), but may not affect the etiologic triggers. 1. Sakane T et al: New England J Med 1999; 341: 1284 . 2.Kaneko S et al: Clin Exp Immunol 1997 108: 204. 3.Hensel M et al: New England J Med 2001; 344: 69. 4.Mancardi GL et al: Neurology 2001; 57: 62. 5.Marmont AM. Haematologica 2002 ; 87 (Suppl to 8) : 24.
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CD34+ selected autologous peripheral blood stem cell transplantation (CD34+/ASCT) for multiple sclerosis E. Carreras, A. Saiz, P. Marín, C. Martínez, M. Rovira, N. Villamor, M. Aymerich, M. Lozano, F. Fernández-Avilés, A. Urbano-Ispizua, J. Berenguer, T. Arbizu, E. Montserrat, F. Graus (Barcelona, E) Aim: To report our experience on CD34+/ASCT for multiple sclerosis (MS) treatment. Design and methods. Patients with advanced secondary progressive (SP) or relapsing-remitting (RR) MS and confirmed worsening of the extended disability status scale (EDSS) in the previous year despite interferon or other immunotherapies were included. Peripheral blood stem cells were obtained by leukaphereses after mobilization with cyclophosphamide (Cy) and G-CSF. CD34+ selection was performed by means of Isolex 300 or CliniMACS devices. BCNU, Cy and ATG were administered as conditioning regimen. Results: Sixteen patients (9 SPMS and 7 RRMS) with a median EDSS of 6.0 (4.5-6.5) and a median of 3 (1-7) relapses in the previous year were included. Mobilization was unsuccessful in one. During mobilization, one patient presented a transient neurologic deterioration. CD34+/ASCT was performed in 15 patients. Main complications during ASCT were engraftment syndrome in three patients, CMV reactivation in one, and neurologic deterioration coinciding with high-fever related to ATG in two. Haematological recovery was fast and complete in all cases. After a median follow up of 34 months (range, 6 -54), EDSS had progressed in two patients, improved in four and remained stable in nine. Despite withdrawal of all immunosuppressive therapy only three patients presented relapses that required treatment. Eleven out of 15 patients had problems with urinary sphincter control before SCT. At one year 7 had clearly improved this function All these facts contributed to subjectively improve the patients' quality of life; but no validated instruments of measurement of this improvement were used. MRI showed disappearance of enhanced T1 lesions but CSF oligoclonal bands persisted in all evaluated cases. Conclusions: Our results show that CD34+/ASCT using BCNU, Cy and ATG as conditioning regimen has an acceptable toxicity and probably reduces the progression of the disease.
Oral Session: Cytokines / Gene therapy O159 All-trans retinoic acid skews monocyte differentiation into IL-12 secreting dendritic-like cells with potent functional activities M. Mohty, S. Morbelli, D. Blaise, D. Isnardon, D. Sainty, B. Gaugler, D. Olive (Marseille, F) Retinoid derivatives are essential agents for multiple biologic processes. All-trans retinoic acid (ATRA) proved to be a potential drug for the treatment of acute promyelocytic leukemia. Numerous immune system dysfunctions can occur in case of retinoid deficiency including atrophy or enlargement of secondary lymphoid organs, changes in lymphocyte counts, altered T, B and NK cell functions, and altered cytokine production. Dendritic cells (DC) play a key role in the initiation of the immune response and are considered promising targets for immunotherapy. Because of their central role in controlling immunity and the wide effects of retinoids on the immune system homeostasis, we assayed the ability of ATRA to influence the differentiation of DCs from circulating peripheral blood monocytes. Here we show that ATRA (10-12 M) and GM-CSF could drive the differentiation of monocytes into dendritic-like cells (ATRA-DC). ATRA-DCs exhibited DC morphology, had a phenotype of immature DCs, with the expression of CD1a, and up-regulation of adhesion and costimulatory molecules. ATRA-DCs could induce a proliferative response in naive CD4+ T cells. Although ATRA-DCs retained their antigen-capture capacity as shown by FITC-Dextran endocytosis, they secreted IL-12p70 without the need for any maturation agent. In addition, ATRA-DCs could drive T cells towards an IL-12-dependent Th1 response with secretion of IFNgamma. Collectively, this is the first study on the effects of ATRA on DC differentiation and functional properties, giving new insights into the mechanisms of action of ATRA. DCs appear to be potential targets for ATRA. The latter provides framework for the development and refinement of ATRA-based immunotherapeutic interventions under stringent biological and cellular monitoring.
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TNF polymorphisms are associated with toxic but not with aGvHD complications in the recipients of allogeneic sibling hematopoietic stem cell transplantation K. Bogunia-Kubik, M. Polak, A. Lange (Wroclaw, PL) 
